1、Target patient populations2025DisclaimerTarget patient populations|20252This presentation includes data from both Novartis published studies as well as third-party sources,as referenced throughout.Such third-party data may include certain assumptions,is included for informational purposes only and h

2、as not been independently verified by Novartis for accuracy or completeness.As a result,no representation or warranty,express or implied,is made as to the accuracy,completeness,or correctness of this information.Cardiovascular,renal and metabolicChronic heart failureTarget patient populations|20254S

3、ources:Cardiovascular Resource Group,IQVIA,Novartis.Data for the year 2025.Epidemiology numbers include patients without access.Diagnosed565Treated15,49812,8308,7441,0483,6962,0107,3213,3881,556565Diagnosed304Treated11,2859,9143,0721,9485,7002,5721,7795,259ChinaJapanEU5USPrevalenceThousand patientsP

4、reserved ejection fractionReduced ejection fractionAtherosclerotic cardiovascular disease Target patient populations|20255LLT Lipid lowering therapy.Lp(a)Lipoprotein(a).Diagnosed refers to patients with established ASCVD.Treated refers to treatment with statin and/or ezetimibe.Advanced LLT include P

5、CSK9i mAbs,Leqvio,bempedoic acid.Elevated Lp(a)goals based on lower of local guidelines and real-world evidence.Guidelines:Elevated Lp(a)if 70 mg/dl,in JP/ES 90 mg/dl.Real-world data:China/Japan 30 mg/dl.Sources:Clarivate/DRG,AHA,ACC,Adelphi/JAMA,IQVIA,INSEE,LAAD,Novartis.Data for year 2025.Epidemio

6、logy numbers include patients without access.524771,7683461,8803,625Elevated Lp(a)209118Tested7,619856ChinaJapanEU5US41126,16413,75818,62634,200Diagnosed13,6109,90513,01419,700Treated4,5576,9095,45311,200Not at goal1,25434884On advanced LLT92,74856,22928,1192,583PrevalenceThousand patientsElevated L